Journal ArticleDOI
Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide
Walter Taal,Dieta Brandsma,Hein G. de Bruin,Jacoline E C Bromberg,Annemarie T. Swaak-Kragten,Peter A. E. Sillevis Smitt,Corine A. van Es,Martin J. van den Bent +7 more
Reads0
Chats0
TLDR
The occurrence of early pseudo‐progression was retrospectively assessed in a cohort of malignant glioma patients treated with RT/TMZ.Abstract:
BACKGROUND. Radiotherapy (RT) plus concomitant and adjuvant temozolomide (TMZ) is now the standard of care for patients with newly diagnosed glioblastoma. The occurrence of pseudo-progression directly after RT is a recognized phenomenon, but to the authors' knowledge its incidence after combined RT/TMZ is unknown. The occurrence of early pseudo-progression was retrospectively assessed in a cohort of malignant glioma patients treated with RT/TMZ. METHODS. The pre-RT and post-RT brain scans from patients treated with RT/TMZ for a malignant glioma were reviewed. Scans were made before the start of RT, 4 weeks after the end of RT, and every 3 months thereafter. In addition, information was collected regarding clinical signs and symptoms, dexamethasone dose, histology, and survival. RESULTS. Eighty-five patients were identified. In 36 patients (42%) the first followup scan 4 weeks after the end of RT indicated disease progression. Of these 36 patients, 18 (50%) were diagnosed with pseudo-progression. None of the patients received additional treatment other than TMZ. Six of 18 patients with pseudo-progression and 12 of the 18 patients with real tumor progression developed new clinical signs and symptoms during RT or in the first 4 weeks thereafter. CONCLUSIONS. Up to 50% of malignant glioma patients treated with RT/TMZ and progression immediately after RT develop pseudo-progression. The current study data support the idea to continue TMZ in the case of progressive lesions immediately after RT/TMZ. Surgery should be considered in symptomatic cases. The inclusion of patients with progressive lesions developing direcdy after chemoradiation in studies regarding recurrent gliomas will lead to an overestimation of the results.read more
Citations
More filters
Journal ArticleDOI
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen,David R. Macdonald,David A. Reardon,Timothy F. Cloughesy,A. Gregory Sorensen,Evanthia Galanis,John DeGroot,Wolfgang Wick,Mark R. Gilbert,Andrew B. Lassman,Christina Tsien,Tom Mikkelsen,Eric T. Wong,Marc C. Chamberlain,Roger Stupp,Kathleen R. Lamborn,Michael A. Vogelbaum,Martin J. van den Bent,Susan M. Chang +18 more
TL;DR: The recognition that contrast enhancement is nonspecific and may not always be a true surrogate of tumor response and the need to account for the nonenhancing component of the tumor mandate that new criteria be developed and validated to permit accurate assessment of the efficacy of novel therapies.
Journal ArticleDOI
Standards of care for treatment of recurrent glioblastoma—are we there yet?
TL;DR: Clinical trials investigating the treatment of recurrent or progressive glioblastoma with nitrosoureas, temozolomide, bevacizumab, and/or combinations of these agents from January 2006 to January 2012 are reviewed.
Journal ArticleDOI
Differentiation between glioma and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides
Jinyuan Zhou,Jinyuan Zhou,Erik Tryggestad,Zhibo Wen,Zhibo Wen,Bachchu Lal,Tingting Zhou,Rachel Grossman,Silun Wang,Kun Yan,De Xue Fu,Eric C. Ford,Betty Tyler,Jaishri O. Blakeley,John Laterra,John Laterra,Peter C.M. van Zijl,Peter C.M. van Zijl +17 more
TL;DR: The amide protons that can be detected by APT provide a unique and noninvasive MRI biomarker for distinguishing viable malignancy from radiation necrosis and predicting tumor response to therapy.
Journal ArticleDOI
Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma.
L.C. Hygino da Cruz,Idia V. Rodríguez,Romeu Côrtes Domingues,Emerson Leandro Gasparetto,A. G. Sorensen +4 more
TL;DR: Pseudoprogression and pseudoresponse are reviewed and how better understanding of these phenomena can aid interpretation are described.
Book
Tumors of the Central Nervous System
TL;DR: The authors have integrated all of these new findings, as well as classical morphological, clinical, and neuroradiological descriptions and illustrations, into an entirely new and completely up-to-date volume that demystifies the complex subject of CNS tumours and tumour-like lesions for general pathologists.
References
More filters
Journal ArticleDOI
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp,Warren P. Mason,Martin J. van den Bent,Michael Weller,Barbara Fisher,Martin J.B. Taphoorn,Karl Belanger,Alba A. Brandes,Christine Marosi,Ulrich Bogdahn,Jürgen Curschmann,Robert C. Janzer,Samuel K. Ludwin,Thierry Gorlia,Anouk Allgeier,Denis Lacombe,J. Gregory Cairncross,Elizabeth Eisenhauer,René O. Mirimanoff +18 more
TL;DR: The addition of temozolomide to radiotherapy for newly diagnosed glioblastoma resulted in a clinically meaningful and statistically significant survival benefit with minimal additional toxicity.
Journal ArticleDOI
Response criteria for phase II studies of supratentorial malignant glioma.
TL;DR: This work suggests "new" response criteria for phase II studies of supratentorial malignant glioma and favor rigorous criteria similar to those in medical oncology, with important modifications, to minimize misinterpretations of response.
Journal ArticleDOI
MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients
Alba A. Brandes,Enrico Franceschi,Alicia Tosoni,V. Blatt,Annalisa Pession,Giovanni Tallini,Roberta Bertorelle,Stefania Bartolini,Fabio Calbucci,Alvaro Andreoli,G. Frezza,Marco Leonardi,F. Spagnolli,Mario Ermani +13 more
TL;DR: PsPD has a clinical impact on chemotherapy-treated GBM, as it may express the glioma killing effects of treatment and is significantly correlated with MGMT status.
Journal ArticleDOI
Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy.
TL;DR: Cerebral necrosis is unlikely at doses below 50 Gy in 25 fractions and the risk increases significantly with increasing radiation dose, fraction size, and the subsequent administration of chemotherapy.
Related Papers (5)
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp,Warren P. Mason,Martin J. van den Bent,Michael Weller,Barbara Fisher,Martin J.B. Taphoorn,Karl Belanger,Alba A. Brandes,Christine Marosi,Ulrich Bogdahn,Jürgen Curschmann,Robert C. Janzer,Samuel K. Ludwin,Thierry Gorlia,Anouk Allgeier,Denis Lacombe,J. Gregory Cairncross,Elizabeth Eisenhauer,René O. Mirimanoff +18 more
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen,David R. Macdonald,David A. Reardon,Timothy F. Cloughesy,A. Gregory Sorensen,Evanthia Galanis,John DeGroot,Wolfgang Wick,Mark R. Gilbert,Andrew B. Lassman,Christina Tsien,Tom Mikkelsen,Eric T. Wong,Marc C. Chamberlain,Roger Stupp,Kathleen R. Lamborn,Michael A. Vogelbaum,Martin J. van den Bent,Susan M. Chang +18 more
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Monika E. Hegi,Annie-Claire Diserens,Thierry Gorlia,Marie-France Hamou,Nicolas de Tribolet,Nicolas de Tribolet,Michael Weller,Johan M. Kros,Johannes A. Hainfellner,Warren P. Mason,Luigi Mariani,Jacoline E C Bromberg,Peter Hau,René O. Mirimanoff,J. Gregory Cairncross,Robert C. Janzer,Roger Stupp +16 more